International journal of obesity (2005) · 2026
Cardiovascular disease and metabolic dysfunction-associated steatotic liver disease incidence in metabolically healthy and unhealthy normal weight obesity.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Johnson Parker R, Keirns Bryant H, Meade Gracie E, Huizinga Parker A, Kim Aiden Y, Sigdel Riju, Cardona Cameron J, Montgomery McKale R, Emerson Sam R, Chowanadisai Winyoo
Аннотация
BACKGROUND: Normal weight obesity (NWO) is characterized by a normal body mass index (BMI) and elevated body fat. Heterogeneous risk has been observed in people with obesity (BMI > 30) when considering metabolic risk factors (MRFs) such as high C-reactive protein, low-density lipoprotein, blood pressure, hemoglobin A1C, triglycerides, and low high-density lipoprotein.
OBJECTIVES: We assessed heterogeneity between metabolically healthy (MH) and metabolically unhealthy (MU) subjects with NWO in relation to (1) incident cardiovascular disease (CVD) and metabolic dysfunction-associated steatotic liver disease (MASLD) along with (2) changes in heart physiology, liver function (assessed with imaging), and cardiometabolic/liver serum biomarkers.
METHODS: In total, 121,586 subjects were classified into the following experimental groups: a healthy normal weight lean reference group ( ≤ 2 MRFs), MH-NWO ( ≤ 2 MRFs), MU-NWO ( > 2 MRFs), and people with overweight/obesity (OW/O) were classified as MH-OW/O ( ≤ 2 MRFs) or MU-OW/O ( > 2 MRFs). Primary outcomes were incident CVD and MASLD analyzed using Firth logistic regression and displayed via odds ratios (OR) and 95%-confidence intervals (95%-CI). Secondary outcomes were cross-sectional cardiac/liver imaging, serum liver enzyme, and lipid biomarkers analyzed using quantile regression. Results were deemed significant at false discovery rate (FDR) < 0.05.
RESULTS: MU-NWO had higher odds of ischemic heart disease (OR 1.68, 95%-CI 1.36-2.05, FDR = 0.000007), myocardial infarction (OR 1.72, 95%-CI 1.38-2.11, FDR = 0.000007), all-cause mortality (OR 1.29, 95%-CI 1.05-1.56, FDR = 0.02), and CVD death (I0-I99); (OR 1.86, 95%-CI 1.27-2.64, FDR = 0.0036) while MH-NWO saw no significant differences. Among female subjects, both MH-NWO (OR 1.37, 95%-CI 1.04-1.78, FDR = 0.03) and MU-NWO (OR 1.78, 95%-CI 1.05-2.83, FDR = 0.03) had increased odds of MASLD. Biochemical and imaging data were consistent with enhanced CVD and MASLD risk.
CONCLUSION: MRFs may modulate CVD and MASLD risk in NWO.
OBJECTIVES: We assessed heterogeneity between metabolically healthy (MH) and metabolically unhealthy (MU) subjects with NWO in relation to (1) incident cardiovascular disease (CVD) and metabolic dysfunction-associated steatotic liver disease (MASLD) along with (2) changes in heart physiology, liver function (assessed with imaging), and cardiometabolic/liver serum biomarkers.
METHODS: In total, 121,586 subjects were classified into the following experimental groups: a healthy normal weight lean reference group ( ≤ 2 MRFs), MH-NWO ( ≤ 2 MRFs), MU-NWO ( > 2 MRFs), and people with overweight/obesity (OW/O) were classified as MH-OW/O ( ≤ 2 MRFs) or MU-OW/O ( > 2 MRFs). Primary outcomes were incident CVD and MASLD analyzed using Firth logistic regression and displayed via odds ratios (OR) and 95%-confidence intervals (95%-CI). Secondary outcomes were cross-sectional cardiac/liver imaging, serum liver enzyme, and lipid biomarkers analyzed using quantile regression. Results were deemed significant at false discovery rate (FDR) < 0.05.
RESULTS: MU-NWO had higher odds of ischemic heart disease (OR 1.68, 95%-CI 1.36-2.05, FDR = 0.000007), myocardial infarction (OR 1.72, 95%-CI 1.38-2.11, FDR = 0.000007), all-cause mortality (OR 1.29, 95%-CI 1.05-1.56, FDR = 0.02), and CVD death (I0-I99); (OR 1.86, 95%-CI 1.27-2.64, FDR = 0.0036) while MH-NWO saw no significant differences. Among female subjects, both MH-NWO (OR 1.37, 95%-CI 1.04-1.78, FDR = 0.03) and MU-NWO (OR 1.78, 95%-CI 1.05-2.83, FDR = 0.03) had increased odds of MASLD. Biochemical and imaging data were consistent with enhanced CVD and MASLD risk.
CONCLUSION: MRFs may modulate CVD and MASLD risk in NWO.